GlassScriptPhysician profile
Seth H Lichtenstein
NPI 1598761041
$3,356.21
in general payments reported to CMS, 2019-2025
31 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $447 · 2021: $606 · 2022: $851 · 2023: $509 · 2024: $353 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,321 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.09 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,507.38 | 2021-2025 | |
| Lilly USA, LLC | $206.68 | 2019-2022 | |
| Allergan, INC. | $193.22 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $168.25 | 2020-2021 | |
| Mdd US Operations, LLC | $123.90 | 2022-2025 | Apokyn, Apokyn |
| Medtronic, INC. | $118.17 | 2023 | Solitaire X |
| Abiomed | $109.80 | 2020 | |
| Lundbeck LLC | $102.72 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $100.40 | 2022-2023 | Ongentys, Ingrezza |
| Impel Pharmaceuticals INC. | $97.65 | 2022 | |
| Genzyme Corporation | $60.23 | 2020-2021 | |
| Heartflow, INC. | $57.72 | 2022 | |
| Novartis Pharmaceuticals Corporation | $56.03 | 2020-2024 | |
| Biohaven Pharmaceuticals, INC. | $38.49 | 2021 | |
| Inspire Medical Systems, INC. | $36.74 | 2025 | Inspire |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36.45 | 2021 | |
| Supernus Pharmaceuticals, INC. | $35.88 | 2020 | |
| Pfizer INC. | $34.13 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $32.81 | 2021 | |
| Alexion Pharmaceuticals, INC. | $28.40 | 2020 | |
| Amneal Pharmaceuticals LLC | $26.27 | 2020-2023 | Rytary |
| Tanabe Pharma America, INC. | $25.79 | 2022 | |
| Eisai INC. | $24.23 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.04 | 2020 | |
| Springworks Therapeutics, INC. | $19.41 | 2025 | |
| Neurelis, INC. | $16.59 | 2020 | |
| Aprecia Pharmaceuticals, LLC | $16.56 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.54 | 2022 | |
| Novo Nordisk INC | $14.38 | 2019 | |
| Biogen, INC. | $14.06 | 2022 | |
| Almatica Pharma LLC | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Lichtenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.